Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Nomura: SINO BIOPHARM (01177.HK) 2025 NP Far Below Forecast Due to One-off Factors
Recommend 6 Positive 6 Negative 5 |
||||
|
||||
|
SINO BIOPHARM (01177.HK)'s 2025 revenue increased by 10% YoY to RMB31.8 billion, in line with management's guidance for double-digit growth and Nomura's expectation, but below the market consensus of RMB33.1 billion, Nomura issued a research report saying. Net profit fell by 33% YoY to RMB2.3 billion, significantly below the market consensus of RMB4.9 billion. Looking ahead to 2026, Nomura believed that the continued rapid growth of innovative drugs, along with collaboration revenue, should help the Company maintain double-digit sales growth. The broker raised its 2026/ 2027 revenue forecasts for the Company by +1.9%/ -1.6%, while cut its earnings estimations by 2.8%/ 7.3%. Therefore, Nomura cut its target price from $9.17 to $8.67, with rating kept at Buy. AASTOCKS Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
